Clinical Trial Update: Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and efficacy of systemic allogeneic NK cells in relapsed/refractory neuroblastoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Systemic allogeneic NK cell therapy (allogeneic natural killer cells)

Snippet

Sponsor: Marzieh Ebrahimi | Conditions: Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB) | Phase 1 | Status: RECRUITING